Skip to content

Solumedrol in Covid-19 infection

High dose solumedrol in patients with severe Covid-19 infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200723048178N3
Enrollment
60
Registered
2021-08-13
Start date
2021-05-03
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 infection. COVID-19, virus identified

Interventions

Intervention 1: Control group: Patients will receive 100 ml saline once daily in addition to the standard therapy for three days. Saline will contain 150 mmol/L sodium and 150 mmol/L chloride and an o

Sponsors

Pakistan Institute of Medical Sciences, Islamabad
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Provide written informed consent Subjects age > 18 years at the time of signing the Informed Consent Form. Male or Female Must have a clinical diagnosis of COVID-19, with at least one clinical symptom (e.g., fever =38°C, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (RT-PCR) testing or equivalent. Individuals with severe COVID-19 symptoms according to Berlin Criteria Hospitalized patients and on Mechanical Ventilation Patients requiring FiO2 of 0.5 or more and a PEEP of 5 mmHg or more Ability to provide informed consent or an authorized representative can sign the informed consent

Exclusion criteria

Exclusion criteria: Pregnant females Patients with HIV infection. Patients with active tuberculosis or a history of treatment for pulmonary tuberculosis Patients with a CrCl of less than 30 ml/minute Patients with heart disease and an ejection fraction of 30% or less Patients with advanced liver disease Patients allergic to methylprednisolone

Design outcomes

Primary

MeasureTime frame
In-hospital mortality. Timepoint: 28 days. Method of measurement: Pre-designed Performa.

Secondary

MeasureTime frame
Duration of hospital stay. Timepoint: 28 days. Method of measurement: Predesigned performa.;Improvement in lung mechanics. Timepoint: 28 days. Method of measurement: predesigned performa.;Improvement in inflammatory markers. Timepoint: 28 days. Method of measurement: predesigned performa.;Incidence of secondary infections. Timepoint: 28 days. Method of measurement: predesigned performa.

Countries

Pakistan

Contacts

Public ContactAhmed Farhan

Pakistan Institute of Medical Sciences

drfarhan992@gmail.com+92 51 9107679

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026